These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30045843)

  • 1. Mouse Population-Based Approaches to Investigate Adverse Drug Reactions.
    Mosedale M
    Drug Metab Dispos; 2018 Nov; 46(11):1787-1795. PubMed ID: 30045843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity.
    Chan SL; Jin S; Loh M; Brunham LR
    Pharmacogenomics; 2015; 16(10):1161-78. PubMed ID: 25978008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic predisposition to adverse drug reactions in the intensive care unit.
    Empey PE
    Crit Care Med; 2010 Jun; 38(6 Suppl):S106-16. PubMed ID: 20502164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics.
    Low SK; Takahashi A; Mushiroda T; Kubo M
    Clin Cancer Res; 2014 May; 20(10):2541-52. PubMed ID: 24831277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of transgenic animals in understanding molecular mechanisms of toxicity.
    Wolf CR; Henderson CJ
    J Pharm Pharmacol; 1998 Jun; 50(6):567-74. PubMed ID: 9680065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Improvement of medication safety by identification of genetically predisposed subjects. Personalized clinical strategies and regulatory advices].
    Lux R; Wärntges S; Bergner S; Kütting B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1545-56. PubMed ID: 24170084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicogenetics: population-based testing of drug and chemical safety in mouse models.
    Rusyn I; Gatti DM; Wiltshire T; Kleeberger SR; Threadgill DW
    Pharmacogenomics; 2010 Aug; 11(8):1127-36. PubMed ID: 20704464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using genome-wide association studies to identify genes important in serious adverse drug reactions.
    Daly AK
    Annu Rev Pharmacol Toxicol; 2012; 52():21-35. PubMed ID: 21819236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: myocardial and infectious adverse reactions as application cases.
    Wang K; Weng Z; Sun L; Sun J; Zhou SF; He L
    Biochem Biophys Res Commun; 2015 Feb; 457(3):249-55. PubMed ID: 25576362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of genetic variation on late toxicities in childhood cancer survivors: A review.
    Clemens E; van der Kooi ALF; Broer L; van Dulmen-den Broeder E; Visscher H; Kremer L; Tissing W; Loonen J; Ronckers CM; Pluijm SMF; Neggers SJCMM; Zolk O; Langer T; Zehnhoff-Dinnesen AA; Wilson CL; Hudson MM; Carleton B; Laven JSE; Uitterlinden AG; van den Heuvel-Eibrink MM
    Crit Rev Oncol Hematol; 2018 Jun; 126():154-167. PubMed ID: 29759558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-associated drug hypersensitivity and the prediction of adverse drug reactions.
    Negrini S; Becquemont L
    Pharmacogenomics; 2017 Oct; 18(15):1441-1457. PubMed ID: 29017379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic mechanisms for variability in drug response and toxicity.
    Linder MW; Valdes R
    J Anal Toxicol; 2001; 25(5):405-13. PubMed ID: 11499898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic diversity in Singaporean populations and Europeans.
    Brunham LR; Chan SL; Li R; Aminkeng F; Liu X; Saw WY; Ong RT; Pillai EN; Carleton BC; Toh D; Tan SH; Koo SH; Lee EJ; Chia KS; Ross CJ; Hayden MR; Sung C; Teo YY
    Pharmacogenomics J; 2014 Dec; 14(6):555-63. PubMed ID: 24861855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development.
    Thompson RA; Isin EM; Li Y; Weaver R; Weidolf L; Wilson I; Claesson A; Page K; Dolgos H; Kenna JG
    Chem Biol Interact; 2011 Jun; 192(1-2):65-71. PubMed ID: 21074519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the epigenome--impact for toxicology.
    Marlowe J; Teo SS; Chibout SD; Pognan F; Moggs J
    EXS; 2009; 99():259-88. PubMed ID: 19157065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update.
    Niemeijer MN; van den Berg ME; Eijgelsheim M; Rijnbeek PR; Stricker BH
    Drug Saf; 2015 Oct; 38(10):855-67. PubMed ID: 26108299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of New Genomic Technologies on Understanding Adverse Drug Reactions.
    Maggo SD; Savage RL; Kennedy MA
    Clin Pharmacokinet; 2016 Apr; 55(4):419-36. PubMed ID: 26369774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling the genetics of common epilepsies: approaches, platforms, and caveats.
    Petrovski S; Kwan P
    Epilepsy Behav; 2013 Mar; 26(3):229-33. PubMed ID: 23103323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicology Strategies for Drug Discovery: Present and Future.
    Blomme EA; Will Y
    Chem Res Toxicol; 2016 Apr; 29(4):473-504. PubMed ID: 26588328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.